ROCKLATAN Drug Patent Profile

Which patents cover Rocklatan, and when can generic versions of Rocklatan launch?

Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rocklatan

Rocklatan was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ROCKLATAN

International Patents:	68
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
Drug Prices:	Drug price information for ROCKLATAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ROCKLATAN
What excipients (inactive ingredients) are in ROCKLATAN?	ROCKLATAN excipients list
DailyMed Link:	ROCKLATAN at DailyMed

See drug prices for ROCKLATAN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ROCKLATAN

NDA:

208259

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ROCKLATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE4
Alcon Research	PHASE4
Oregon Health and Science University	PHASE4

See all ROCKLATAN clinical trials

Pharmacology for ROCKLATAN

Drug Class	Rho Kinase Inhibitor
Mechanism of Action	Rho Kinase Inhibitors

Paragraph IV (Patent) Challenges for ROCKLATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for ROCKLATAN

ROCKLATAN is protected by seventeen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes			Y	Y

Expired US Patents for ROCKLATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019

International Patents for ROCKLATAN

When does loss-of-exclusivity occur for ROCKLATAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ROCKLATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010241996
Australia	2010242800
Australia	2016201754

Supplementary Protection Certificates for ROCKLATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3053913	301038	Netherlands		PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3053913	122020000016	Germany		PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119

Last updated: July 23, 2026

ROCKLATAN (Netarsudil + Latanoprost) market dynamics and financial trajectory

Executive summary: ROCKLATAN (netarsudil 0.02% + latanoprost 0.005% ophthalmic solution) has remained a focused glaucoma product addressing large unmet need across ocular hypertension and open-angle glaucoma. Market performance has been driven by (1) formulary access through payer contracting, (2) differentiation versus prostaglandin monotherapy via fixed-dose dual therapy, (3) substitution risk from generic latanoprost and competitive fixed-dose combinations, and (4) ongoing access expansion in the US while international adoption follows local practice patterns. Financial trajectory is best viewed through net product sales momentum, prescription conversion at initiation, and switching rates versus latanoprost, netarsudil monotherapy, and competing combination regimens.

What is ROCKLATAN and how does it fit glaucoma treatment dynamics?

ROCKLATAN is a fixed-dose combination of:

• Netarsudil (Rho kinase inhibitor, increases trabecular outflow and reduces episcleral venous pressure)
• Latanoprost (prostaglandin analog, increases uveoscleral outflow)

The product targets patients with ocular hypertension (OHT) and open-angle glaucoma (OAG) who require additional intraocular pressure (IOP) lowering beyond prostaglandin monotherapy or who are candidates for combination therapy.

How do prescribers sequence therapy in OAG/OHT?

US glaucoma prescribing typically follows:

1. Start with prostaglandin analogs (strong first-line efficacy and dosing convenience).
2. Add agents when targets are not met, commonly via fixed combinations to reduce drop burden and improve adherence.
3. Switch within mechanisms or add different classes based on tolerability (notably corneal and conjunctival tolerability).

Fixed-dose combinations are favored when they:

• reduce total instillation burden,
• simplify adherence,
• align with payer step edits.

What key outcomes drive adoption?

Adoption depends on three commercial variables:

• IOP reduction consistency relative to comparator regimens.
• Tolerability and discontinuation rates tied to known class adverse effects (notably corneal/conjunctival events associated with Rho kinase inhibitors).
• Formulary placement as payers use step therapy and prior authorization to manage net prices.

How large is the addressable glaucoma market for ROCKLATAN?

The addressable market is the US prevalent population treated for OAG/OHT plus newly diagnosed cases. Commercial opportunity is shaped by:

• high chronicity and long-term follow-up,
• frequent regimen changes when targets are missed,
• the tendency to use additional IOP lowering as disease progresses.

The fixed-dose combination segment grows when:

• patients need multi-mechanism coverage early,
• adherence becomes a major determinant of realized effectiveness,
• payers prefer competitive fixed-dose brands to manage rebate intensity and net cost.

What are the market dynamics shaping ROCKLATAN uptake and pricing?

Formulary access and contracting

ROCKLATAN’s market dynamics are dominated by:

• payer contracting for brand ophthalmics,
• PBM formulary tiering and preferred-brand status,
• step edits that direct patients to latanoprost first unless combination coverage is justified.

Commercially, even modest formulary positioning changes can materially impact share in ophthalmology, since prescribers often align with plan incentives after initial adoption.

Replacement risks from generics and “component pricing”

A key structural factor is that latanoprost is generic in the US. This creates a pricing pressure environment for combination products:

• Component-based cost comparisons push payers to negotiate rebates aggressively.
• Patients can be managed with latanoprost plus netarsudil as separate prescriptions if available at favorable net prices.

ROCKLATAN’s ability to sustain net sales growth relies on negotiating cost-effectiveness versus the “separate drops” alternative, including the incremental value of fixed dosing.

Competition from other fixed-dose glaucoma combinations

ROCKLATAN competes with other combination regimens combining:

• prostaglandin analogs with additional classes (commonly beta-blockers, carbonic anhydrase inhibitors, or other agents depending on available products),
• as well as newer pipeline entrants that target adherence and tolerability.

Combination competition is not only about efficacy. It is about:

• tolerability profile differences that affect persistence,
• dosing schedule,
• payer access that can shift patients across classes.

How does ROCKLATAN compare with latanoprost monotherapy and netarsudil monotherapy?

Latanoprost monotherapy: price anchor and switching baseline

Because latanoprost generics are inexpensive, switching away from monotherapy typically requires:

• evidence of insufficient IOP control,
• tolerability justification,
• and payer acceptance of combination coverage.

Netarsudil monotherapy: class differentiation but adherence and persistence

Netarsudil as a standalone therapy can capture a subset of patients who fail prostaglandin therapy or who need additional outflow mechanisms. Fixed-dose dual therapy tends to outperform in commercial metrics when:

• patients prefer fewer bottles,
• clinicians aim for early multi-mechanism IOP control,
• and persistence improves with simpler dosing.

What is the financial trajectory of ROCKLATAN: sales growth, persistence, and maturity signals?

ROCKLATAN’s financial trajectory is best assessed through:

• annual net sales trend and quarterly cadence,
• prescription and script-to-patient conversion,
• market share vs combination peers,
• persistence (how long patients remain on therapy before switching or discontinuation),
• and the net price trajectory after rebates.

Maturity dynamics

As a brand stabilizes, growth typically transitions from:

• new patient initiation to
• conversion from competitor regimens (monotherapy or other combinations).

At maturity, the main drivers shift to:

• share gains through payer contracting,
• channel inventory management,
• and competition intensity from other combinations.

Margin drivers

Ophthalmology brands’ margins are heavily influenced by:

• rebate intensity,
• contracting with major payers,
• wholesaler purchasing patterns,
• and gross-to-net compression in competitive environments.

When does ROCKLATAN lose exclusivity, and how does that affect financial forecasts?

ROCKLATAN’s exclusivity and patent landscape determines generic risk timing, settlement behavior in Paragraph IV frameworks, and the shape of late-stage sales tapering.

Because exclusivity and patent expiry are fact-specific to:

• each jurisdiction,
• formulation or method-of-use claims,
• and Orange Book listing records, a precision exclusivity timeline must be built from Orange Book and patent family data.

Under typical ophthalmology brand economics, financial forecasts incorporate:

• pre-expiry pricing pressure (rebate escalation as generic threat approaches),
• “line extension” strategy risk (if any),
• and post-expiry volume substitution speed depending on substitution laws and payer switching.

What is the Orange Book status of ROCKLATAN and what patents matter most?

Orange Book status is the key source for:

• listed patents (drug substance, formulation, method of use),
• expiration dates,
• and whether a generic applicant can be blocked or incentivized to launch via noninfringing pathways.

For combination ophthalmics, the most consequential claims often include:

• formulation or stability claims (if present),
• method-of-use claims (if any),
• and any combination-specific claims that strengthen barriers to generic approval.

Are there generic or biosimilar risks for ROCKLATAN?

ROCKLATAN is an ophthalmic small-molecule product. The relevant competitive threat is:

• generic small-molecule competition once regulatory and patent barriers allow.

Because this is not a biologic, “biosimilar risk” is not the correct competitive vector. Instead, risk is evaluated using:

• Paragraph IV filings (if any),
• potential settlements that define launch triggers,
• and whether generic entrants can maintain label parity.

What patent litigation affects ROCKLATAN commercialization?

Any product liability or market-blocking litigation can shape commercial timing through:

• injunction risk,
• settlement milestones,
• launch delay agreements.

For brand economics, litigation impacts are often realized as:

• adjusted forecast uncertainty,
• payer contracting behavior in the shadow of settlement,
• and wholesalers’ order patterns.

Has ROCKLATAN faced Paragraph IV challenges and what do settlements mean for launch timing?

For small-molecule products, Paragraph IV challenges and settlements determine:

• whether generic entry occurs at first eligible date,
• whether “at-risk” launch happens,
• and whether brand revenue declines sharply or decelerates.

Settlement terms can include:

• agreed launch dates,
• non-launch covenants,
• market-sharing or carve-out language,
• and stipulations tied to patent validity or enforceability.

What regulatory milestones influence ROCKLATAN demand in the US?

Demand is influenced by:

• FDA approval timing (initial and any supplements),
• label scope,
• and safety updates that affect clinician willingness to prescribe.

For ophthalmics, incremental label expansions can shift conversion patterns and increase eligible patient segments, affecting prescriptions and refill cycles.

Which companies compete with ROCKLATAN and how strong are their commercial positions?

ROCKLATAN competes against:

• prostaglandin monotherapies (including generics),
• netarsudil monotherapy,
• and fixed-dose combination alternatives used in OAG/OHT.

Competitive strength typically reflects:

• depth of payer contracting,
• presence on formularies and preferred tiers,
• persistence and tolerability outcomes in real-world use,
• and availability of multiple strengths or delivery formats.

What manufacturing and supply dynamics matter for ROCKLATAN?

Ophthalmic solutions have supply chain constraints tied to:

• sterile manufacturing and fill-finish capacity,
• stability constraints for liquid formulations,
• and regulatory compliance.

In the financial trajectory, supply disruptions typically show up as:

• temporary demand suppression,
• backorder-driven channel destocking,
• and catch-up sales later.

What are the key commercial scenarios for ROCKLATAN over the next 3 to 5 years?

Market scenarios typically run on three axes:

1. Uptake velocity driven by formulary penetration and patient conversion.
2. Price and rebate trajectory driven by competitive entries and payer leverage.
3. Exclusivity and launch timing driven by patent expiry and regulatory approval windows.

A plausible base-case structure for forecasting brand ophthalmics:

• continued growth from conversion of monotherapy and competing combinations,
• deceleration toward mid-single to low double-digit growth as the market matures,
• accelerated competitive pressure as generic threats approach.

Key commercial metrics to track for ROCKLATAN performance

For market and investor monitoring, the metrics that best map to revenue are:

• prescriptions (scripts) growth vs market segment,
• share of new starts into combination therapy,
• persistence rates and discontinuation drivers tied to adverse events,
• channel inventory and wholesaler purchasing cadence,
• gross-to-net changes (rebates and discounts),
• payer mix and prior authorization outcomes.

Key Takeaways

• ROCKLATAN’s commercial performance is driven by its fixed-dose combination value proposition in OAG/OHT, anchored on IOP lowering plus adherence convenience.
• Growth is sensitive to formulary placement and payer contracting, and constrained by generic cost anchors from latanoprost monotherapy.
• Financial trajectory depends on net price and rebate intensity as combination competition intensifies.
• Future revenue risk is dominated by exclusivity and patent expiry mechanics, which determine generic launch timing and whether brand sales taper or step down.

FAQs

1. What share does ROCKLATAN hold versus other fixed-dose glaucoma combinations in major US plan formularies?
2. How do corneal and conjunctival adverse events influence ROCKLATAN persistence and switching rates?
3. What is the typical time-to-switch from ROCKLATAN to other combination regimens after IOP target non-achievement?
4. How does prior authorization affect ROCKLATAN conversion from latanoprost monotherapy?
5. What Orange Book patents are most likely to be asserted in generic opposition to ROCKLATAN?

References (APA)

1. FDA. (n.d.). Drugs@FDA: ROCKLATAN (netarsudil and latanoprost ophthalmic solution). U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (ROCKLATAN). U.S. Food and Drug Administration.
3. FDA. (n.d.). NDA/BLA and labeling information for ROCKLATAN. U.S. Food and Drug Administration.

DrugChatter Q&A for ROCKLATAN

Rocklatan cost with insurance?
How much does rocklatan cost?
Rocklatan eye drops price?
Rocklatan prescribing information?
What is rocklatan eye drops used for?